GlassScriptPhysician profile
Stanislaw Bryjak
NPI 1932159126
$16,075.84
in general payments reported to CMS, 2019-2025
60 companies · $2,426 in 2025
The $2,426 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $830 · 2021: $1,877 · 2022: $2,509 · 2023: $3,159 · 2024: $3,312 · 2025: $2,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,824 · Education: $73.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,823.74 |
| Education | $73.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,994.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,780.62 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $1,081.37 | 2019-2025 | |
| Lilly USA, LLC | $971.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $959.93 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $717.87 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $671.45 | 2019-2025 | Gardasil 9, Belsomra, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $663.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.53 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $608.20 | 2019-2024 | Farxiga, Fasenra |
| E.R. Squibb & Sons, L.L.C. | $549.27 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $446.58 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $400.91 | 2023-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $399.71 | 2023-2025 | Rexulti |
| Dexcom, INC. | $331.79 | 2021-2025 | Dexcom G6 Transmitter |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanislaw Bryjak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.